Patents by Inventor Ralph Leon Biemans
Ralph Leon Biemans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131136Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.Type: ApplicationFiled: November 1, 2023Publication date: April 25, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Elisabeth Marie Monique BERTAUD, Ralph Leon BIEMANS, Nicolas Jean Benoit MONIOTTE, Laurent Bernard Jean STRODIOT
-
Patent number: 11844828Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.Type: GrantFiled: October 19, 2016Date of Patent: December 19, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Elisabeth Marie Monique Bertaud, Ralph Leon Biemans, Nicolas Jean Benoit Moniotte, Laurent Bernard Jean Strodiot
-
Publication number: 20220354941Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.Type: ApplicationFiled: June 30, 2022Publication date: November 10, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
-
Patent number: 11400147Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.Type: GrantFiled: January 12, 2018Date of Patent: August 2, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Publication number: 20220211859Abstract: This application relates to methods for the production of polysaccharide antigen-carrier protein conjugates, in particular conjugates of Group B Streptococcus (GBS) capsular polysaccharide and a carrier protein, in particular CRM197. The methods comprise a hydroxyapatite chromatography step in order to separate the conjugate from free polysaccharide and free carrier protein.Type: ApplicationFiled: May 7, 2020Publication date: July 7, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ralph Leon BIEMANS, Elisabeth Marie Monique BERTAUD
-
Patent number: 11241495Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: GrantFiled: November 2, 2018Date of Patent: February 8, 2022Assignee: Glaxosmithkline Biologicals S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 10669318Abstract: The present invention relates to a process for conjugation of an antigen.Type: GrantFiled: March 5, 2012Date of Patent: June 2, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
-
Patent number: 10646564Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.Type: GrantFiled: February 21, 2019Date of Patent: May 12, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Publication number: 20200000911Abstract: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).Type: ApplicationFiled: February 5, 2019Publication date: January 2, 2020Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20190298822Abstract: present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: ApplicationFiled: November 2, 2018Publication date: October 3, 2019Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20190262447Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.Type: ApplicationFiled: February 21, 2019Publication date: August 29, 2019Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Patent number: 10279033Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.Type: GrantFiled: January 5, 2016Date of Patent: May 7, 2019Assignee: GlaxoSmithKline Biologicals SAInventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Patent number: 10245317Abstract: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).Type: GrantFiled: September 14, 2016Date of Patent: April 2, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 10166287Abstract: present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: GrantFiled: August 30, 2017Date of Patent: January 1, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20180303923Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.Type: ApplicationFiled: October 19, 2016Publication date: October 25, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Elisabeth Marie Monique BERTAUD, Ralph Leon BIEMANS, Nicolas Jean Benoit MONIOTTE, Laurent Bernard Jean STRODIOT
-
Publication number: 20180250389Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.Type: ApplicationFiled: January 5, 2016Publication date: September 6, 2018Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
-
Publication number: 20180207262Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.Type: ApplicationFiled: January 12, 2018Publication date: July 26, 2018Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
-
Publication number: 20180104322Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.Type: ApplicationFiled: December 5, 2017Publication date: April 19, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Philippe Thomas DENOEL, Pierre DUVIVIER, Carine GORAJ
-
Patent number: 9931397Abstract: The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 1:2-1:5, and wherein at least one different capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 5:1-1:1.99.Type: GrantFiled: June 23, 2006Date of Patent: April 3, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20180064806Abstract: present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: ApplicationFiled: August 30, 2017Publication date: March 8, 2018Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman